Elite Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELTP research report →
About the company
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals.
- CEO
- Nasrat Hakim
- IPO
- 2000
- Employees
- 64
- HQ
- Northvale, NJ, US
Price Chart
- Market Cap
- $366.18M
- P/E
- 8.72
- P/S
- 2.46
- P/B
- 3.70
- EV/EBITDA
- -711.65
- Div Yield
- 0.00%
- Gross Margin
- 50.15%
- Op Margin
- 33.56%
- Net Margin
- 30.14%
- ROE
- 62.22%
- ROIC
- 0.03%
- Revenue
- $148.87M · 77.13%
- Net Income
- $44.87M · 1140.01%
- EPS
- $0.04 · 1145.00%
- Op Income
- $49.96M
- FCF YoY
- 462778.09%
- 52W High
- $0.74
- 52W Low
- $0.33
- 50D MA
- $0.36
- 200D MA
- $0.46
- Beta
- 0.38
- Avg Volume
- 585.23K
Get TickerSpark's AI analysis on ELTP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 9, 26 | Plassche Douglas | other | 2,500,000 |
| Jan 9, 26 | Plassche Douglas | other | 2,500,000 |
| Oct 2, 25 | Plassche Douglas | sell | 800,000 |
| Aug 25, 25 | ELITE PHARMACEUTICALS INC /NV/ | other | 2,500,000 |
| Aug 25, 25 | ELITE PHARMACEUTICALS INC /NV/ | other | 2,500,000 |
| Aug 22, 25 | ELITE PHARMACEUTICALS INC /NV/ | sell | 500,000 |
| Jul 10, 25 | Kirkov Kirko | buy | 16,366 |
| Jul 8, 25 | Plassche Douglas | sell | 200,000 |
| Jul 3, 25 | Plassche Douglas | other | 2,500,000 |
| Jul 3, 25 | Plassche Douglas | other | 2,500,000 |
Our ELTP coverage
Recent articles, reports, and earnings notes.
No research on ELTP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELTP report →Similar companies
Peers in the same neighborhood.